Review - 09/02/2023 5th Gene Technology Report – a critical observation of a cutting-edge technology The societal importance of genetic technologies was demonstrated during the coronavirus pandemic, when it was possible to rapidly develop suitable vaccines thanks to genetic engineering methods. As a result, the Fifth Gene Technology Report published in autumn 2021 reads like a validation of many years of work, as well as making it clear that the will to continue the detailed long-term monitoring is very much present.https://www.gesundheitsindustrie-bw.de/en/article/news/5th-gene-technology-report-critical-observation-cutting-edge-technology
Press release - 25/11/2022 Praise for Ulm's trauma research from DFG CRC 1149 reaches 3rd funding phase What a success for Ulm University and its medical centre! The German Research Foundation (Deutsche Forschungsgemeinschaft; DFG) extends the Collaborative Research Centre (CRC) on Trauma Medicine for the second time. The third funding phase infuses the CRC 1149 'Danger Response, Disturbance Factors and Regenerative Potential after Acute Trauma' with 11.1 million euros. https://www.gesundheitsindustrie-bw.de/en/article/press-release/praise-ulms-trauma-research-dfg-crc-1149-reaches-3rd-funding-phase
Press release - 19/10/2022 Apogenix’ Asunercept Demonstrates Efficacy in Phase II Trial for the Treatment of Hospitalized COVID-19 Patients Apogenix, a biopharmaceutical company developing next generation immunotherapeutics, announced today that asunercept showed statistically significant benefits for hospitalized COVID-19 patients in the ASUNCTIS trial. The open-label multi-center phase II trial investigated efficacy and safety of asunercept in 435 patients with moderate to severe COVID-19 disease.https://www.gesundheitsindustrie-bw.de/en/article/press-release/apogenixs-asunercept-zeigt-wirksamkeit-phase-ii-studie-zur-behandlung-von-covid-19-patienten-im-krankenhaus
Press release - 30/08/2021 CureVac Preclinical Data Demonstrates Significant Reduction of Liver Fibrosis with mRNA Therapeutic CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the publication entitled “Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model” in the peer-reviewed Journal of Hepatology.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-preclinical-data-demonstrates-significant-reduction-liver-fibrosis-mrna-therapeutic
Vaccine development - 25/05/2021 Vaccines - a beacon of hope in the fight against pandemics https://www.gesundheitsindustrie-bw.de/en/article/dossier/vaccines-beacon-hope-fight-against-pandemics
Funding Novartis announces broad range of initiatives to respond to COVID-19 Pandemic Funding programme, Funded by: Novartis AGhttps://www.gesundheitsindustrie-bw.de/en/database/funding/novartis-announces-broad-range-initiatives-respond-covid-19-pandemic
Article - 16/04/2019 Tumour monitoring using liquid biopsy Liquid biopsy, the analysis of cancer biomarkers and circulating tumour cells in body fluids such as blood, is revolutionising the diagnosis and monitoring of cancer. It has also been possible to expand circulating tumour cells from the blood under laboratory conditions. It is expected that in the future, liquid biopsy will be able to precisely characterise tumour cells at every stage of a cancer.https://www.gesundheitsindustrie-bw.de/en/article/news/tumour-monitoring-using-liquid-biopsy
Dossier - 05/08/2013 Progress expands bioethical boundaries https://www.gesundheitsindustrie-bw.de/en/article/dossier/progress-expands-bioethical-boundaries
Dossier - 21/05/2013 No new drugs to be placed on the market without clinical trials New pharmaceuticals are subject to approval by drug authorities. Prior to approval of a new pharmaceutical several hurdles such as preclinical and clinical studies need to be cleared. Clinical trials are performed to ensure the quality efficacy and safety of a medicinal product. Clinical development is a time-consuming and costly process and takes on average ten to fifteen years before a pharmaceutical company can apply for the approval of the…https://www.gesundheitsindustrie-bw.de/en/article/dossier/no-new-drugs-to-be-placed-on-the-market-without-clinical-trials
Dossier - 26/11/2012 Genetic diagnostics technology reaches the limits of what is medically reasonable Rapid progress in sequencing technologies is poised to set the imagination of biomedical researchers on fire. Experts now believe that progress is about to make possible what seemed to be utopian a few years ago – it seems likely that it will soon be possible to sequence the human genome in only a few minutes and store and automatically analyse it using tiny automates. However, is everything that is technically feasible also reasonable?https://www.gesundheitsindustrie-bw.de/en/article/dossier/genetic-diagnostics-technology-reaches-the-limits-of-what-is-medically-reasonable
Dossier - 09/07/2012 Bachelors and masters under scrutiny has the new study system stood the test? More practical relevance, shorter courses and courses that are compatible across Europe – when the decision to implement the bachelor’s and master’s system was made in Germany in 1999, there were high expectations and hopes for the positive changes to come. The question is, have these expectations been met? The time is now ripe for universities and companies to review the progress that has been made in achieving the goals of the Bologna…https://www.gesundheitsindustrie-bw.de/en/article/dossier/bachelor-s-and-master-s-under-scrutiny-has-the-new-study-system-stood-the-test